Abstract
The mechanism of the augmentation of adenosine action by 1, 4-bis-[3-(3, 4, 5-trimethoxybenzoyl-oxy)-propyl] perhydro-1, 4-diazepine (dilazep I, N, N,) and dipyridamole on the coronary vessel was examined in the dog. Cororary blood flow was measured by applying a Morawitz cannula to the in vivo heart. It was found that the ratio of coronary vasodilating activity of adenosine administered into saphenous vein, right atrium, and left atrium was 1:1.5: 30, and that coronary vasodilating actions of adenosine administered into saphenous vein, right atrium, and left atrium after dilazep (10 μg/kg, i.v.) were 15.6, 10.8, and 3.3 times greater than those without dilazep, respectively. After dipyridamole coronary vasodilating actions of adenosine administered into saphenous vein, right atrium, and left atrium were 17.5, 14.3, and 5.4 times greater. These results indicate that augmentation of coronary vasodilating action of intravenously administered adenosine by dilazep or dipyridamole was mainly exerted at the lung and myocardium, and slightly in the blood, and was due to inhibition of the disappearance of adenosine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
